静脉血栓塞栓症在产科患者的预防
Emma L Klaserner1, Kayla J Popova1, Rikki-Leigh Gaudet1
1Department of Pharmacy, University of Michigan Health Department of Pharmacy Services, Ann Arbor, MI, USA.
Journal of pharmacy practice
|April 15, 2024
概括
静脉血栓栓塞 (VTE) 是导致产妇死亡的主要原因. 本综述讨论了怀孕期间的VTE风险以及抗凝血剂预防在产科患者预防血栓的作用.
科学领域:
- 产科 产科 产科 产科 产科
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉血栓塞栓症 (VTE),包括肺栓塞 (PE) 和深静脉血栓症 (DVT),是发达国家产妇死亡的主要原因.
- 怀孕期间的生理适应会产生高凝血状态,在产科患者中显著增加VTE风险.
- 目前的指导方针缺乏对孕妇进行验证的VTE风险评估工具,以及关于预防性抗凝剂策略的共识.
研究的目的:
- 审查孕期增加VTE风险背后的病理生理机制.
- 检查有关VTE在产科患者中药理学预防的有效性和安全性的现有文献.
- 强调需要基于证据的风险分层和治疗方案,以预防VTE在这个人群中.
主要方法:
- 对怀孕期间凝血变化研究的文献综述.
- 对高危产科患者预防性抗凝剂使用的研究分析.
- 综合了有关VTE发病率,风险因素和产科人口预防策略的数据.
主要成果:
- 怀孕引起的高凝血是VTE的重要驱动因素.
- 预防性抗凝剂显示出在高风险孕妇中减少静脉血栓发作事件的潜力.
- 在美国,验证的风险评估工具和标准化预防方案存在缺陷.
结论:
- 了解与怀孕相关的凝血障碍对于预防VTE至关重要.
- 药物预防是减轻风险产科患者风险的关键策略之一.
- 开发经过验证的风险评估工具和共识指南对于在怀孕期间最佳的VTE管理至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
Esophageal Varices-II: Clinical Features and Management
60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60


